Here are relevant reports on : european-injectable-drug-delivery-market

• Pulmonary/ Respiratory Drug Delivery Market by Formulation (Type (Solution, Suspension, Dry powder), Device Type (Metered dose, Dry Powder, Nebulizer)), Canister (Plain, Coated), End User (Hospitals, Homecare), Applications (COPD) - Global Forecast to 2021

  The global pulmonary drug delivery market is projected to reach USD 52.37 Billion by 2021 from USD 36.10 Billion in 2016, at a CAGR of 6.5% during the forecast period. Growth in this market is mainly driven by increasing preference of pulmonary route as an alternate route of drug delivery, rising focus on the development of smart/digital inhalers and increasing incidence of respiratory diseases such as COPD, asthma, and cystic fibrosis. Emerging markets such as India, China, & Japan and growth in online marketing channels are expected to offer lucrative growth opportunities for market players in the coming years. On the other hand, factors such as regulatory issues and pricing pressures are the major factors restraining market growth.

  • Published: February 2017
  • Price: $ 4950
  • TOC Available:

• Live Cell Encapsulation Market by Technique (Dripping (Simple, Electrostatic), Coaxial Airflow, Liquid Jet), Polymer (Alginate, Chitosan, Silica, Cellulose Sulfate), Application (Probiotics, Transplant, Drug Delivery, Research) - Forecast to 2024

  The live cell encapsulation market is projected to grow to USD 303 million by 2024 from USD 250 million in 2018, at a CAGR of 3.2% during the forecast period. Growth in the live cell encapsulation market is primarily driven by factors such as the increasing public-private investments to support product development, increasing research to establish the clinical efficacy of cell encapsulation technologies, and rising public awareness related to the clinical role of encapsulated cells in disease management. BioTime, Inc. (US), Viacyte, Inc. (US), and Living Cell Technologies Ltd. (Australia) were the top three players in the live cell encapsulation market. Other prominent players operating in this market include Sigilon Therapeutics, Inc. (US), Evonik Industries (Germany), BÜCHI Labortechnik AG (Germany), Blacktrace Holdings Ltd (UK), and Sernova Corporation (Canada), among others. Furthermore, the key players in the developmental pipeline products in this market include Neurotech Pharmaceuticals, Inc. (US), Gloriana Therapeutics (US), Kadimastem (Israel), Beta-O2 Technologies, Inc. (Israel), Defymed (France), and Altucell, Inc. (US), among others.

  • Published: April 2019
  • Price: $ 4950
  • TOC Available:

• Europe Medical Tubing Market by Material (Plastics, Rubber, Specialty Polymers), Application (Bulk Disposable Tubing, Catheters & Cannulas, Drug Delivery Systems), Structure (Single Lumen, Multi Lumen, Co-Extruded, Braided), and Country - Forecast to 2030

  The Europe medical tubing market is projected to grow from USD 3.64 billion in 2025 to USD 5.14 billion by 2030, at a CAGR of 7.1% during the forecast period. The key global players in the Europe medical tubing market are Freudenberg Medical (US), RAUMEDIC AG (Germany), Vygon (France), B. Braun (Germany), Saint-Gobain (France), Trelleborg Medical (Sweden), Teleflex (US), Coloplast (Denmark), Smiths Medical (US), and TE Connectivity (Ireland).

  • Published: April 2026
  • Price: $ 4950
  • TOC Available:

• European Smart Homes and Assisted Living - Advanced Technologies and Global Market (2009-2014)

  The European (retrofit) smart homes and assisted living market is a niche market with a significant growth potential, driven primarily by the increase in the ageing population (65 years-80 years) in the European Union. UK, Germany, and the Scandinavian countries are expected to dominate the market due to the tendency of the aged to live separately from their children and ready acceptance of the smart homes concept in these countries.

  • Published: November 2009
  • Price: $ 4950
  • TOC Available:

• European Smart Homes and Assisted Living Market (2010 – 2015)

  The European smart home market generated $1,544.3 million in 2010 and is expected to generate $3,267 million in 2015 with a CAGR of 16.2% from 2010-2015. . It is segmented into security, lighting, heating, ventilating and air conditioning (HVAC), entertainment, energy management, and others. The European smart home market comprises Northern Europe, Eastern Europe, Western Europe, Southern Europe, and others.

  • Published: April 2011
  • Price: $ 4950
  • TOC Available:

• European Union Vehicle Market -Trends and forecast to 2019

  The European Union is the world’s second largest manufacturer of vehicles. The automobile industry is a major contributor to the region’s GDP and one of its top employers.

  • Published: May 2026
  • Price: $ 4950
  • TOC Available:

• Bio-Implants Market - by Type (Cardiovascular, Spine, Orthopedics, Trauma, Dental), by ROA (Surgical/Injectable), by Origin (Allo/Auto/Xenograft, Synthetic) & Materials (Ceramics, Biomaterial, Alloys, Polymers) - Global Trends &, Forecasts till 2017

  Bio-implants can be defined as prostheses used to regularize physiological functions. They are made up of biosynthetic materials like collagen, and tissue-engineered products like artificial skin or tissues. Most bioengineered products like cardiac pacemakers and orthopedic artificial implants are also covered under bio-implants, since they are implanted entirely in the patient’s body.

  • Published: September 2012
  • Price: $ 4950
  • TOC Available:

• Injectable Pharma Packaging Market by Type (Prefilled Syringes, Vials, Ampoules, Cartridges), Packaging Type (Primary, Secondary), Application (Chronic Disease Management, Vaccines, Biologics, Insulin, Oncology), and Region-Global Forecast to 2030

  Injectable Pharma Packaging Market is projected to reach USD 98.8 billion by 2030 from USD 44.8 billion in 2025, at a CAGR of 17.5% during the forecast period. The key players in the injectable pharma packaging market include Schott AG (Germany), Gerresheimer AG (Germany), West Pharmaceutical Services (US), Stevanato Group (Italy), BD (Becton, Dickinson and Company) (US), SGD Pharma (France), Nipro Corporation (Japan), AptarGroup (US), Catalent, Inc. (US), and Datwyler Group (Switzerland).

  • Published: April 2026
  • Price: $ 4950
  • TOC Available:

• Veterinary Biologics Market by Product (Monoclonal Antibodies, Diagnostic Kits, Immunoglobulins & Antitoxins), RoA (Injectable, Oral), Application (Infectious Disease Prevention, Dermatology, Pain Management), Animal, End User - Global Forecast to 2030

  The global veterinary biologics market, valued at US$2.61 billion in 2024, stood at US$2.72 billion in 2025 and is projected to advance at a resilient CAGR of 5.2% from 2024 to 2030, culminating in a forecasted valuation of US$3.51 billion by the end of the period. The market growth is fueled by increasing demand for effective animal therapeutics, rising populations of livestock and companion animals, and greater awareness of animal health and disease prevention.

  • Published: October 2025
  • Price: $ 4950
  • TOC Available:

• Companion Animal Pharmaceuticals Market by Animal Type (Dogs, Cats, Horses), Route of Administration (Oral, Injectable, Topical), Indication (Antibiotics, Parasiticides), Distribution Channel (Veterinary Hospitals & Clinics) & Region - Global Forecasts to 2027

  The global companion animal pharmaceuticals market in terms of revenue was estimated to be worth $14.4 billion in 2022 and is poised to reach $19.6 billion by 2027, growing at a CAGR of 6.3% from 2022 to 2027. Major players operating in the market Zoetis Inc. (US), Merck & Co., Inc. (US), Boehringer Ingelheim GmbH (Germany), Elanco Animal Health Incorporated (US), Ceva Santé Animale (France), Virbac (France), Vetoquinol S.A. (France), Dechra Pharmaceuticals plc (UK) are some of the market players.

  • Published: March 2023
  • Price: $ 4950
  • TOC Available:

• FIRST
• PREVIOUS

Records 41 to 50 of 50